StreetInsider.com News Articles

Form DEF 14A Salarius Pharmaceuticals For: Feb 24

Fri, 09 Jan 2026 17:09:00 -0500

si-local-file:///var/storage/secattach/20260109/25831994.html

Form DEF 14A Salarius Pharmaceuticals For: Feb 24

Fri, 09 Jan 2026 17:09:00 -0500

si-local-file:///var/storage/secattach/20260109/25831994.html

Form DEF 14A Salarius Pharmaceuticals For: Feb 24

Fri, 09 Jan 2026 17:09:00 -0500

si-local-file:///var/storage/secattach/20260109/25831994.html

Form 8-K Salarius Pharmaceuticals For: Jan 08

Thu, 08 Jan 2026 12:38:00 -0500

si-local-file:///var/storage/secattach/20260108/25825564.html

Form 8-K Salarius Pharmaceuticals For: Jan 08

Thu, 08 Jan 2026 12:38:00 -0500

si-local-file:///var/storage/secattach/20260108/25825564.html

Salarius Pharmaceuticals changes name to Decoy Therapeutics, ticker to DCOY

Wed, 07 Jan 2026 08:46:08 -0500

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) announced it will change its corporate name to Decoy Therapeutics Inc. and begin trading under the ticker symbol DCOY on the Nasdaq Capital Market starting January 8, 2026.

The name change reflects the company's focus on developing peptide-conjugate therapeutics through its proprietary platform. The changes do not affect the total number of shares outstanding, shareholders' rights, the CUSIP number, transfer agent, company operations, or leadership structure.

"Changing our corporate name is another step in our transformation to developing the next generation of peptide-conjugate therapeutics, with an initial emphasis on high-priority viral and oncology targets," said Rick Pierce,

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Wed, 07 Jan 2026 08:45:00 -0500

Trading under DCOY to commence on January 8, 2026

Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection

Capital-efficient 2026 plan features advancing lead antiviral into the clinic while expanding pipeline and partnership opportunities

CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) (Salarius) announces it will change its corporate name to Decoy Therapeutics Inc. (Decoy) and its common shares will trade on the Nasdaq Capital Market under the ticker symbol DCOY effective as of commencement of trading on January 8, 2026. These changes reflect

Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics

Wed, 07 Jan 2026 08:45:00 -0500

Trading under DCOY to commence on January 8, 2026

Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection

Capital-efficient 2026 plan features advancing lead antiviral into the clinic while expanding pipeline and partnership opportunities

Salarius Pharmaceuticals faces Nasdaq delisting over stock price

Fri, 02 Jan 2026 17:16:42 -0500

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) received notice from Nasdaq on December 31, 2025, stating the company fails to meet minimum bid price requirements for continued listing on The Nasdaq Capital Market.

The company's stock closed below $1.00 per share for 30 consecutive business days, violating Nasdaq listing rule 5550(a)(2). Due to the company's status under a Mandatory Panel Monitor and a reverse stock split within the prior year, Salarius is not eligible for the standard 180-day compliance period typically granted to companies facing delisting.

Unless Salarius appeals the delisting determination by January 7, 2026, its securities will be suspended from trading at

Form 8-K Salarius Pharmaceuticals For: Dec 31

Fri, 02 Jan 2026 17:15:00 -0500

si-local-file:///var/storage/secattach/20260102/25799251.html

Form 8-K Salarius Pharmaceuticals For: Dec 31

Fri, 02 Jan 2026 17:15:00 -0500

si-local-file:///var/storage/secattach/20260102/25799251.html

Form 4 Salarius Pharmaceuticals For: Dec 30 Filed by: HANISH ARNOLD C

Fri, 02 Jan 2026 17:14:00 -0500

si-local-file:///var/storage/secattach/20260102/25799250.html

Form 4 Salarius Pharmaceuticals For: Dec 30 Filed by: HANISH ARNOLD C

Fri, 02 Jan 2026 17:14:00 -0500

si-local-file:///var/storage/secattach/20260102/25799250.html

Form 8-K Salarius Pharmaceuticals For: Dec 31

Fri, 02 Jan 2026 17:13:00 -0500

si-local-file:///var/storage/secattach/20260102/25799248.html

Form 8-K Salarius Pharmaceuticals For: Dec 31

Fri, 02 Jan 2026 17:13:00 -0500

si-local-file:///var/storage/secattach/20260102/25799248.html

Form PRE 14A Salarius Pharmaceuticals For: Feb 24

Mon, 29 Dec 2025 16:26:00 -0500

si-local-file:///var/storage/secattach/20251229/25786356.html

Form PRE 14A Salarius Pharmaceuticals For: Feb 24

Mon, 29 Dec 2025 16:26:00 -0500

si-local-file:///var/storage/secattach/20251229/25786356.html

Form DEFA14A Salarius Pharmaceuticals

Fri, 19 Dec 2025 16:38:00 -0500

si-local-file:///var/storage/secattach/20251219/25765430.html

Form DEFA14A Salarius Pharmaceuticals

Fri, 19 Dec 2025 16:38:00 -0500

si-local-file:///var/storage/secattach/20251219/25765430.html

Form 8-K Salarius Pharmaceuticals For: Dec 19

Fri, 19 Dec 2025 16:31:00 -0500

si-local-file:///var/storage/secattach/20251219/25765321.html

Form 8-K Salarius Pharmaceuticals For: Dec 19

Fri, 19 Dec 2025 16:31:00 -0500

si-local-file:///var/storage/secattach/20251219/25765321.html

Salarius adjourns annual meeting due to insufficient quorum

Fri, 19 Dec 2025 11:13:15 -0500

Salarius Pharmaceuticals Inc. (NASDAQ: SLRX) adjourned its 2025 annual stockholder meeting on December 19 due to insufficient voter turnout and will reconvene the meeting on December 31, 2025.

The company required a quorum of 34% of outstanding shares entitled to vote but received proxies representing approximately 30% of outstanding common stock as of the October 24 record date. The reconvened meeting will be held virtually at 10:00 a.m. Central Time via webcast.

The adjournment allows Salarius additional time to solicit votes for proposals outlined in its definitive proxy statement filed with the Securities and Exchange Commission on November 7, 2025. The record

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Fri, 19 Dec 2025 11:12:00 -0500

HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (“Salarius” or the “Company”) today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for and convened on December 19, 2025 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the “SEC”) on November 7, 2025.

The required quorum for the transaction of business at the Annual Meeting is 34% of the outstanding shares entitled to

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Fri, 19 Dec 2025 11:12:00 -0500

The required quorum for the transaction of business at the Annual Meeting is 34% of the outstanding shares entitled to

Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

Fri, 19 Dec 2025 11:12:00 -0500

The required quorum for the transaction of business at the Annual Meeting is 34% of the outstanding shares entitled to